Featured Articles

1. Spotlight On India: Regulatory Enhancements, Modernization, And Robust Data Collection 7/25/2024

   Explore India's adoption of global best practices, 24/7 work cycles, and audit readiness to ensure high standards of Good Clinical Practice, attract more trials, and provide robust data to stakeholders.

2. Patient Diversity: Identifying Challenges, Opportunities, And Best Practices 4/10/2024

   By listening to the voice of patient diversity and implementing FDA guidance measures, learn how stakeholders can improve trust, engagement, data reliability, patient outcomes, and promote public health.

3. Consider India For Your Next HCC International Trial 11/16/2023

   Assess the feasibility of India as a potential venue for HCC trials as well as its epidemiology, historical perceptions, and untapped potential for international clinical research opportunities.

4. Elevated Risk: Exploring The Links Between Chronic Kidney Disease And Cardiovascular Disease 2/4/2022

   Chronic kidney disease has become inextricably linked with cardiovascular conditions, a discovery that has yielded synergistic diagnosis and intervention methods. Dr. Jamie Dwyer explores the connection between these two diseases, which has brought about a sort of renaissance for nephrology research.

5. No Shortcuts: Two Pathways To Building A Future For Huntington's Disease Research 11/16/2021

   One of the tenets of clinical research is that findings often result in more questions than answers. For Huntington’s disease, the journey toward understanding and treatment continues to be a methodical one. Dr. Ole Isacson highlights two pathways to ongoing research for this rare disease.

6. The Missing Minority: Understanding The Three Main Barriers To Diversity In Today's Clinical Trials 10/12/2021

   While there are socioeconomic factors contributing to the reasons behind the lack of diversity, the exclusion of minority populations in clinical trials can be a scientifically flawed misstep. By focusing on a single demographic, clinical research findings become limited, and by ignoring other representative populations, "unexpected" side effects may be more commonplace while treatment success levels will vary.

7. Identifying & Understanding Differentiators In CAR T Cell Therapy 8/23/2021

   Hematologist Dr. Robert S. Negrin takes a deep dive into identifying and understanding the central differentiators in cell therapy clinical trials.

8. It Takes Two – The Importance Of Study Partners In Alzheimer's Disease Clinical Trials 8/23/2021

   Alzheimer’s Disease currently afflicts close to 50 million people worldwide, highlighting the importance of clinical trials for this condition. Alzheimer’s studies are unique in that they require an additional participant to assess the patient’s mental and physical health during the trial. But what are the characteristics of a viable study partner?

9. What Sets Oncology Clinical Studies Apart From Other Trials? Four Top Differentiators 7/22/2021

   Oncology trials may start out similarly to other therapeutic indications, but they differ radically in relation to early phases of the study, biomarkers, drug characteristics, and competition for patients.  In this article, Dr. Alex Adjei speaks about the top four differentiators in oncology studies that make them unique among other trials.

10. Managing Alzheimer's Trials In A Diverse Global Environment 7/22/2021

    Diagnostics and treatment for Alzheimer’s Disease vary – both around the world and around the block. In this article, read how recognizing the common disparities for these clinical trials, ranging from standards of care to lack of diversity, brings sponsors and other stakeholders closer to maintaining standardized protocols for Alzheimer’s studies.